Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00257205
Status:
COMPLETED
Last Update Posted:
2012-07-02
First Post:
2005-11-18
Brief Title:
CP-675206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase 3 Open Label Randomized Comparative Study Of CP-675206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 3 multi-national open-label 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy or biochemotherapy for the treatment of metastatic disease The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675206 with that of patients who are randomized to receive either dacarbazine or temozolomide investigator choice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None